Browse News
Filter News
Found 320 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
4/8/2024
AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) programs at the American Association for Cancer ResearchⓇ (AACR) Annual Meeting 2024 at the San Diego Convention Center, with three posters being presented on April 8 and one on April 9.
-
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
4/3/2024
AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
-
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
3/19/2024
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time).
-
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
3/12/2024
Rallybio Corporation today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent program and corporate developments.
-
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
3/11/2024
AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
-
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
3/5/2024
AbCellera announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center.
-
AbCellera to Present at Upcoming Investor Conferences in March 2024
2/23/2024
AbCellera announced that executives from the Company will present at the following investor conferences.
-
AbCellera Announces Resignation of Board Member
2/23/2024
AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024.
-
AbCellera Reports Full Year 2023 Business Results
2/20/2024
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023.
-
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
2/15/2024
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.
-
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
2/6/2024
Rallybio Corporation announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116.
-
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
1/23/2024
AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
-
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
1/4/2024
Rallybio Corporation provided an update on recent accomplishments and announced expected 2024 milestones.
-
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
12/20/2023
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
-
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
11/16/2023
AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).
-
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
11/3/2023
AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
-
AbCellera Reports Q3 2023 Business Results
11/2/2023
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2023.
-
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
11/1/2023
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.
-
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
11/1/2023
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results.